FIELD: medicine.
SUBSTANCE: invention relates to medicine and concerns a method for the prevention or therapy of acute respiratory distress syndrome on a model of induced ARDS in laboratory animals, modeled using lipopolysaccharide, by its endotracheal administration, followed by induction of an inflammatory cellular signaling pathway and the use of experimental prevention or therapy of ARDS, consisting in the introduction before or after ARDS modeling of a drug based on ezrin-peptide Thr-Glu-Lys-Lys-Arg-Arg-Glu-Thr-Val-Glu-Arg-Glu-Lys-Glu at a dose of 0.2 mg to 1 mg per animal.
EFFECT: invention provides a reduction in the risk of dependence of the results of therapy on the methods for administration of the drug; reduction of the toxic effects of ARDS therapy; increased resistance of the body in the treatment of ARDS against infections caused by viruses, bacteria and fungi; inhibition of inflammatory cytokines that cause ARDS.
3 cl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF ENISAMIUM IODIDE FOR THE PREVENTION AND/OR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | 2022 |
|
RU2799328C1 |
| PRODUCT AND METHOD FOR MUCUS VISCOSITY NORMALIZATION | 2014 |
|
RU2750211C2 |
| COMPOSITIONS OF ANTI-CD6 ANTIBODIES AND METHODS OF TREATING AND REDUCING NEGATIVE CONSEQUENCES OF CORONAVIRUS, INCLUDING COVID-19 | 2021 |
|
RU2828013C1 |
| PHARMACEUTICAL COMPOSITION WITH ANTI-INFLAMMATORY ACTION | 2022 |
|
RU2801579C1 |
| ANTIBODIES AGAINST HUMAN VSIG4 AND APPLICATION THEREOF | 2019 |
|
RU2776638C1 |
| SYNTHETIC ANALOGS OF IL-10 | 1997 |
|
RU2194054C2 |
| THERAPEUTIC RNA FOR OVARIAN CANCER | 2020 |
|
RU2832172C2 |
| USE OF IL-18-BINDING PROTEIN (IL-18BP) IN INFLAMMATORY DISEASES | 2014 |
|
RU2731713C2 |
| ANTIBODY AGAINST ADRENOMEDULLIN (ADM), OR FRAGMENT OF ANTI-ADM ANTIBODY, OR ANTI-ADM NON-IG FRAME FOR USE IN INTERVENTION AND THERAPY OF HYPEREMIA IN PATIENT | 2017 |
|
RU2762059C2 |
| CYCLIC PROTEIN CONTAINING NO CYSTEINE RESIDUES | 2008 |
|
RU2486196C2 |
